Jordan Gauthier, MD

Articles by Jordan Gauthier, MD

Rationale for Ibrutinib/CAR T-Cell Therapy Combination in CLL

January 9th 2019

Jordan Gauthier, MD, MSc, discusses the rationale for combining ibrutinib with CD19-targeting chimeric antigen receptor T cells for the treatment of patients with chronic lymphocytic leukemia.

Latest Updated Articles

Rationale for Ibrutinib/CAR T-Cell Therapy Combination in CLL
Published: January 9th 2019 | Updated: